Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
"Receipt of Orphan Drug Designation from the FDA for PBGENE-DMD underscores the tremendous unmet need and urgency to deliver safe treatments that significantly improve muscle function over time for boys living with Duchenne muscular dystrophy," said Cindy Atwell, Chief Development and Business Officer at Precision BioSciences. "This regulatory milestone builds on our recent receipt of Rare Pediatric Disease designation and, together with our preclinical body of evidence, gives us tremendous confidence as we move this program towards the clinic. Looking ahead, we remain in active dialogue with the FDA as we advance PBGENE-DMD toward regulatory milestones, with clinical data anticipated in 2026."
The FDA grants Orphan Drug Designation to drugs and biologics intended for the treatment, diagnosis, or prevention of rare diseases or conditions affecting fewer than 200,000 people in the United States. Orphan Drug Designation provides sponsors certain benefits, including financial incentives to support clinical development and the potential for up to seven years of market exclusivity for the drug for the designated orphan indication in the U.S. if the drug is ultimately approved for that use.
About PBGENE-DMD
PBGENE-DMD is Precision's development program for the treatment of DMD. The approach uses two complementary ARCUS nucleases delivered via a one-time administration in a single AAV to excise exons 45-55 of the dystrophin gene with the aim of restoring near full-length dystrophin protein within the body to improve functional outcomes. PBGENE-DMD is intended to address up to 60% of the DMD patient population.
In preclinical studies, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and produced significant, durable functional improvements in a humanized DMD mouse model. PBGENE-DMD restored the body's ability to produce a near full-length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement.
PBGENE-DMD was recently granted FDA Rare Pediatric Disease (RPD) designation for the treatment of DMD. The Company is advancing the final IND-enabling toxicology studies and is working closely with leading DMD clinicians to design a first in human trial optimized for safety and efficacy. Clinical grade material is in preparation, with initial clinical data expected in 2026.
About Precision BioSciences, Inc.
Precision's two lead programs, PBGENE-HBV, for chronic Hepatitis B, and PBGENE-DMD, for Duchenne muscular dystrophy, are focused on areas with large patient populations with high unmet need. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company's pipeline prioritizes in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our and our partners' and licensees' product candidates and gene editing approaches; the potential of PBGENE-DMD to safely drive meaningful improvement in functional and durable benefit over time for up to 60% of patients with DMD; the design on PBGENE-DMD to permanently edit a patient's own DNA sequence, resulting in naturally-produced, near full-length dystrophin protein proven known to be functional in humans; the benefits of an Orphan Drug Designation including financial incentives and regulatory exclusivity; the potential value of a Priority Review Voucher(if awarded) including priority review for a different product or sale to another sponsor; the expected timing of regulatory processes and clinical operations (including IND and/or CTA filings, studies, enrollment and clinical data for PBGENE-DMD; and anticipated timing of clinical data. In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "appear," "approach," "believe," , "confidence", "contemplate," "could," "design" "designed," "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should," "strive," "suggest," "target," "will," "would," or the negative thereof and similar words and expressions.
Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim "top-line" and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.
All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723491398/en/
Contacts
Investor and Media Contact: Naresh TannaVice President of Investor Relationsnaresh.tanna@precisionbiosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
9 minutes ago
- CNN
Trump fires a senior official over jobs numbers
Donald Trump Job market EconomyFacebookTweetLink Follow President Donald Trump has fired Dr. Erika McEntarfer, the commissioner of the Bureau of Labor Statistics, whom he accused, without evidence, of manipulating the monthly jobs reports for 'political purposes.' The BLS' monthly labor report Friday showed that the US economy added only 73,000 jobs in July, far below expectations. It also sharply revised down the employment growth that had been previously reported in May and June – by a combined 258,000 jobs. After the revisions, the jobs report showed the weakest pace of hiring for any three-month period since the pandemic recession in 2020. 'In my opinion, today's Jobs Numbers were RIGGED in order to make the Republicans, and ME, look bad,' Trump said in a Truth Social post. Although the May and June jobs numbers were worse than initially believed, revisions are normal in this process. The BLS' initial monthly jobs estimates are often based on incomplete data, so they are revised twice after the initial report — followed by an annual revision every February. Additionally, BLS economists use a formula to smooth out jobs numbers for seasonal variations and that can exacerbate revisions when they fall outside economists' expectations. Trump on Friday incorrectly called the revisions a 'mistake.' 'McEntarfer said there were only 73,000 Jobs added (a shock!) but, more importantly, that a major mistake was made by them, 258,000 Jobs downward, in the prior two months,' Trump said on Truth Social. 'Similar things happened in the first part of the year, always to the negative. The Economy is BOOMING under 'TRUMP.'' Trump said McEntarfer 'faked' the jobs numbers before the election to try to boost former Vice President Kamala Harris' chances in the 2024 presidential election. 'We're doing so well. I believe the numbers were phony, just like they were before the election, and there were other times. So, you know what I did? I fired her, and you know what? I did the right thing,' Trump told reporters Friday on the South Lawn. McEntarfer was confirmed by the Senate 86-8 in January 2024 for a term of four years. CNN has reached out to McEntarfer for comment. Until Trump replaces McEntarfer, Deputy Commissioner William Wiatrowski will serve as Acting Commissioner, the administration said. Trump has previously criticized the BLS for its jobs data and revisions, and he told reporters Friday evening he's 'always had a problem with these numbers.' In 2016, during his first presidential campaign, Trump claimed that the unemployment rate was significantly higher than the BLS let on. In 2024, he accused former President Joe Biden's administration of orchestrating a cover-up, after the BLS reported that it had overcounted jobs by 818,000 over the previous 12 months. 'I was thinking about it this morning, before the numbers that came out. I said, 'Who is the person that does these numbers?' And then they gave me stats about before the election,' Trump said Friday. 'We need people that we can trust,' he added. But Trump and his administration have also praised the BLS data when it has been favorable to them. During Trump's first term, former White House Press Secretary Sean Spicer said in March 2017 that the jobs data was no longer 'phony' after the BLS issued a strong jobs report. And a month ago, current White House Press Secretary Karoline Leavitt posted on social media that the economy had beat expectations for jobs in four straight BLS labor reports. The BLS is nonpartisan, and businesses and government officials rely on the accuracy of its data to make determinations about investment, hiring, spending and all sorts of key decisions. 'It's outrageous for anyone in government to question the integrity of the BLS,' said Jason Furman, a Harvard professor and former Obama economic adviser. 'Accurate statistics are essential to the economy.' Furman doubted that replacing McEntarfer would compromise the BLS, but he said even the possibility or appearance of that notion 'would be bad.' 'Countries that have tried to fake those statistics have often ended up with economic crises as a result,' Furman said. Mark Zandi, chief economist at Moody's Analytics, said the BLS' data is at the 'highest standard,' and 'as accurate as it can be.' 'Anything that undermines that or even the perception of that high standard is deeply worrisome,' Zandi said. 'I've never seen anything even close to this.' At Moody's, Zandi said he has hired a number of former BLS economists whom he called 'fantastic.' 'They do great work,' Zandi said. 'They are critical to a well-functioning economy.' Democratic Virginia Senator Mark Warner accused Trump of working the referees. 'Firing the ump doesn't change the score,' Warner said in a statement. 'Americans deserve to know the truth about the state of the Trump economy.' But Labor Secretary Lori Chavez-DeRemer said in a post on social media that she supports replacing McEntarfer. 'A recent string of major revisions have come to light and raised concerns about decisions being made by the Biden-appointed Labor Commissioner,' Chavez-DeRemer said on X. 'I support the President's decision to replace Biden's Commissioner and ensure the American People can trust the important and influential data coming from BLS.' The BLS jobs survey is widely considered by economists to be robust. It samples more than 100,000 businesses and government agencies each month, representing roughly 629,000 individual worksites. But, as part of larger cost-cutting taking place around practically every part of Trump's government, the BLS is laying off staff — and, as a result, reducing the scope of its work. For example, the BLS posted a notice in June stating it stopped collecting data for its Consumer Price Index in three cities (Lincoln, Nebraska; Buffalo, New York; and Provo, Utah) and increased 'imputations' for certain items (a statistical technique that, when boiled down to very rough terms, essentially means more educated guesses). That worried Federal Reserve Chair Jerome Powell. In testimony before Congress in June, Powell said he believed the BLS data to be accurate, but he was upset about what could become a trend. 'I wouldn't say that I'm concerned about the data today, although there has been a very mild degradation of the scope of the surveys,' Powell said at the time, in response to a question about survey data quality. 'But I would say the direction of travel is something I'm concerned about.' This story has been updated with additional developments and context.
Yahoo
9 minutes ago
- Yahoo
Are US tariffs starting to bite? Trump, in denial over rising prices, targets Fed chief Powell
Memo from the White House: inflation is 'right on track', it declared this week, citing the latest official data. Price growth is now 'very low', according to Donald Trump. The actual statistics paint a markedly different picture. Just six months after he regained power, in part by promising to rapidly reduce prices, Trump has presided over the chaotic rollout of tariffs on an array of overseas products that many have argued risk having the exact opposite effect. After a lull, the consumer price index (CPI) is back on the rise. In June, everything from fruit and washing machines to dresses and toys became more expensive. Businesses in the US and around the world have struggled to keep up with the Trump administration's erratic rollout of its aggressive trade strategy: the daily White House soap opera of warnings, threats, confusion, deadlines, delays and drama. Related: Can Trump fire Federal Reserve chair Jerome Powell? Putting to one side the steady stream of twists, cliffhangers and all-caps declarations, each episode has pushed US tariffs higher. The overall average effective tariff rate is now set to hit 20.6%, according to the non-partisan The Budget Lab at Yale, its highest level since 1910. Eventually, someone has to foot the bill. Interactive By Trump's telling, the countries he targets will be forced to pay up. But in reality, tariffs are paid by the importer – US-based companies, in this case – and often passed on. Tariffs are a burden. One way or another, the impact typically is felt along each link of the supply chain, from the initial manufacturer to the customer who buys the finished product. 'All through that chain, people will be trying not to be the ones who pick up the cost,' noted Jerome Powell, the Federal Reserve chair, at a recent press conference. 'But ultimately, the cost of the tariff has to be paid and some of it will fall on the end consumer,' added Powell. 'We know that. That's what businesses say. That's what the data says from past evidence. So we know that's coming.' The effect is not immediate, though. It might take Trump a matter of minutes to announce a tariff on Truth Social, but the full effects can take months to work their way through the economy. Interactive And so Powell, and the Fed, has waited. For seven months now, at four consecutive meetings, the US central bank's policymakers have sat on their hands and kept interest rates on hold. After dramatically raising rates to combat inflation, they want to see how prices respond to Trump's tariffs before cutting them back. It's early days. Prices are still rising, and by more than the Fed's target of 2% each year. Officials want to know if Trump's plan will make them rise faster. The evidence has so far been mixed. While consumer price growth accelerated slightly between May and June, the annual rate of wholesale price growth slipped. The Fed's latest 'beige book', a semi-quarterly report of anecdotal economic insights from across the US, also released this week, described a relatively calm business landscape, despite persisting uncertainty. Assuming Trump's announced tariffs are enforced, they will dent US economic growth by 0.1 percentage point this year and 0.3 percentage points next, according to modeling by Oxford Economics. 'The drag on the economy is predominantly tied to core inflation, which will temporarily be 0.2bps [basis points] higher than in the current baseline,' said its chief US economist, Ryan Sweet. 'Though the boost to consumer prices is modest, it still reduces growth in real disposable income and, by extension, consumer spending.' Inside the Fed's headquarters in Washington DC, Powell and his officials are patiently monitoring the data while deciding their next steps. But less than a mile away, one man is not prepared to wait. In a series of increasingly bitter attacks, Trump has publicly lambasted Powell for being 'too late' to cut rates, and claimed the Fed's inaction is costing the US economy. He has called on Powell (whom he first tapped to be Fed chair in 2017) to quit, and unnerved Wall Street by raising the prospect of firing him. Bharat Ramamurti, former deputy director of the national economic council under Joe Biden, said: 'If you replace Jay Powell with someone who is clearly doing whatever Donald Trump wants them to do, expectations about what inflation is going to do in the long run are going to spike and that's going to create a real problem for the Fed in the long term.' The supreme court signaled it views the Fed chair as legally shielded from presidential removal, describing the central bank as a 'uniquely structured, quasi-private entity' in a May ruling about two of Trump's other firings. Trump is 'highly unlikely' to fire Powell, he has asserted, before floating one reason he might have to go: a $2.5bn renovation of the Fed's buildings. 'I mean, it's possible there's fraud involved,' the president claimed. Powell has reportedly asked the central bank's inspector general to review the project. Powell is due to finish his term in May, and has stressed he will remain in post until then. Advocates of the Fed's independence insist the more important question is not whether the president can remove him before then, but if he should. 'Once you no longer have the check of the central bank, which can raise interest rates as needed to curb inflation, you really start to raise the specter of runaway costs, runaway inflation, and it makes the US economy less attractive for investors domestically and abroad,' said Ramamurti. Inflation is 'right on track', according to his administration. Economists are already concerned it is tilting off course – and Trump won't rule out taking action that critics warn would shunt it off the rails altogether.
Yahoo
9 minutes ago
- Yahoo
Trump steps up attacks on Fed's independence amid interest rates row
Donald Trump called on top Federal Reserve officials to seize control from its chair, Jerome Powell, if he fails to cut interest rates, stepping up his extraordinary attacks on the central bank's independence. The US president called Powell 'a stubborn MORON' in a series of critical social media posts on Friday, days after the Fed held rates steady for the fifth consecutive time. It comes as Trump faces heightened questions over the impact of his aggressive economic policy, and the White House presses forward with plans for a fresh wave of tariffs next week. Hours before the federal government released data which underlined a significant deterioration in the jobs market, Trump again broke with precedent to pin blame on the Fed – and urge it to change course. 'Jerome 'Too Late' Powell, a stubborn MORON, must substantially lower interest rates, NOW,' Trump wrote on Truth Social, his social network. 'IF HE CONTINUES TO REFUSE, THE BOARD SHOULD ASSUME CONTROL, AND DO WHAT EVERYONE KNOWS HAS TO BE DONE!' Related: Divided Fed leaves interest rates unchanged despite Trump pressure The Fed chair does not unilaterally set interest rates, which are decided by its rate-setting Federal Open Market Committee. Presidents typically respect its independence, leaving the central bank to make an objective decision – without political interference – about the best policy on interest rates for the US economy. 'Too Little, Too Late. Jerome 'Too Late' Powell is a disaster,' Trump wrote, minutes after Friday's lackluster jobs report. 'DROP THE RATE! The good news is that Tariffs are bringing Billions of Dollars into the USA!' Powell has repeatedly argued that the best approach for the Fed right now is to wait and see the impact of Trump's aggressive tariff strategy before cutting rates. But Trump has increasingly used the Powell, whom he appointed during his first term, as something of a piñata – repeatedly accusing him of damaging the US economy. Two members of the Fed's rate-setting committee dissented from its other policymakers' call to hold rates steady this week, and – to the president's delight – published their reasons on Friday. 'STRONG DISSENTS ON FED BOARD,' Trump wrote, claiming: 'IT WILL ONLY GET STRONGER!' By Friday evening, however, Trump's tone appeared to have changed as he told Newsmax during an interview that Powell will 'most likely' stay in his position. Trump said he would remove Powell 'in a heartbeat' and said the Fed's interest rate was too high but added that others have said Powell's removal would 'disturb the market'. 'He gets out in seven or eight months and I'll put somebody else in,' Trump said. On Friday afternoon, another member of the committee abruptly resigned. Adriana D Kugler, whose term was set to expire in January, announced she would step down next week. She did not provide a reason for the move, and will return to Georgetown University as a professor in the fall. 'I am especially honored to have served during a critical time in achieving our dual mandate of bringing down prices and keeping a strong and resilient labor market,' Kugler said in a statement. Her resignation creates a vacancy for the White House to fill. Reuters contributed reporting Sign in to access your portfolio
